Wednesday, March 7

Follow-up to Megan's post on March 5: Merck & Co. is feeling the pressure of a tainted corporate image as well as competition from generic drug companies. Yesterday the company announced that it is slashing the prices for two of its important AIDS-fighting drugs in Africa by 40% to 50%. An act of good conscience? Probably not. Afraid of losing market share? Probably. Pick up a copy of today's Wall Street Journal for the front page.